Y-mAbs Therapeutics
YMAB61
$8.110.00%$8.11
YMAB61
$8.11
0.00%Performance History
| Key Stats | |
|---|---|
| Open | $7.98 |
| Prev. Close | $0.00 |
| EPS | -0.54 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 7.43 | 8.11 |
| 52 Week Range | 4.69 | 20.90 |
| Ratios | |
|---|---|
| EPS | -0.54 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
About Y-mAbs Therapeutics (YMAB)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Thomas Gad
- Headquarters
- New York
- Employees
- 147
- Exchange
- NASDAQ
Keep an eye on Y-mAbs Therapeutics
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Y-mAbs Therapeutics (YMAB) stock price performance year to date (YTD)?
As of the latest data, Y-mAbs Therapeutics (YMAB) has a year-to-date price change of -1.03%. Over the past month, the stock has experienced a price change of -34.27%. Over the last three months, the change has been -41.34%. Over the past six months, the figure is -34.5%. Looking at a longer horizon, the five-year price change stands at -74.59%.
help
What is Y-mAbs Therapeutics 's (YMAB) price per share?
The current price per share for Y-mAbs Therapeutics (YMAB) is $7.75. The stock has seen a price change of $7.75 recently, indicating a 0% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Y-mAbs Therapeutics (YMAB)?
For Y-mAbs Therapeutics (YMAB), the 52-week high is $20.9, which is 169.71% from the current price. The 52-week low is $4.69, the current price is 65.22% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Y-mAbs Therapeutics (YMAB) a growth stock?
Y-mAbs Therapeutics (YMAB) has shown an average price growth of -4.94% over the past three years. It has received a score of 38 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Y-mAbs Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
Is Y-mAbs Therapeutics (YMAB) a profitable company?
Y-mAbs Therapeutics (YMAB) has a net income of -$21.43M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 86.54% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -42.52% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $84.82M, with a revenue growth rate of 29.96%, providing insight into the company's sales performance and growth. The gross profit is $73.4M. Operating income is noted at -$25.67M. Furthermore, the EBITDA is -$23.35M.
help
What is the market capitalization of Y-mAbs Therapeutics (YMAB)?
Y-mAbs Therapeutics (YMAB) has a market capitalization of $350.7M. The average daily trading volume is 7.53, indicating the stock's liquidity and investor engagement.